VBI 2902
Alternative Names: VBI-2902; VBI-2902aLatest Information Update: 13 Aug 2024
At a glance
- Originator National Research Council Canada; VBI Vaccines
- Developer VBI Vaccines
- Class COVID-19 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 31 May 2024 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Canada (IM) prior to May 2024 (VBI Vaccines pipeline, May 2024)
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Canada (IM, Injection)
- 14 Nov 2022 VBI Vaccines completes a phase Ia/Ib trial in COVID-2019 infections (Prevention) in Canada (IM) (NCT04773665)